Effect of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis C virus infection

Hepatology Research

Volumn 39, Issue 1, 2009, Pages 21-30

  Nojiri, Shunsuke ^a   Nakao, Haruhisa ^a   Sugauchi, Fuminaka ^a   Miyaki, Tomokatsu ^a   Senda, Katsuhiro ^a   Sasaki, Makoto ^a   Kataoka, Hiromi ^a   Kamiya, Takeshi ^a   Nakazawa, Takahiro ^a   Ohara, Hirotaka ^a   Orito, Etsuro ^b   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Biliary bile acid; Chronic hepatitis C virus; Serum bile acid; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; BILE ACID; CHENODEOXYCHOLIC ACID; LIVER ENZYME; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID METABOLISM; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEPATOBILIARY SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; LIVER CELL; LIVER PROTECTION; MALE; PRIORITY JOURNAL;

EID: 58149178580     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00406.x     Document Type: Article

References (59)

1. Poupon R, Chretien Y, Poupon RE et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834-6.
2. Beuers U, Spengler U, Kruis W et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial. Hepatology 1992; 16: 707-14.
3. O'Brien CB, Senior JR, Arora-Mirchandani R et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30-month pilot study. Hepatology 1991; 14: 838-47.
4. Crosignani A, Battezzati PM, Setchell KD et al. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose-response study. Hepatology 1991; 13: 339-44.
5. Rolandi E, Franceschini R, Cataldi A et al. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Eur J Clin Pharmacol 1991; 40: 473-6.
6. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
7. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501-6.
8. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-10.
9. Saez-Royuela F, Porres JC, Moreno A et al. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: A randomized, controlled trial. Hepatology 1991; 13: 327-31.
10. Marcellin P, Boyer N, Giostra E et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-7.
11. Tarao K, Takemiya S, Tamai S et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997; 79: 688-94.
12. Tarao K, Rino Y, Ohkawa S et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999; 86: 589-95.
13. Tarao K, Rino Y, Ohkawa S et al. Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. Cancer 2002; 94: 1787-95.
14. Kitani K, Kanai S. Effect of ursodeoxycholate on the bile flow in the rat. Life Sci 1982; 31: 1973-85.
15. Sagawa H, Tazuma S, Kajiyama G. Protection against hydrophobic bile salt-induced cell membrane damage by liposomes and hydrophilic bile salts. Am J Physiol 1993; 264: G835-9.
16. Heuman DM, Mills AS, McCall J et al. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology 1991; 100: 203-11.
17. Guldutuna S, Zimmer G, Imhof M et al. Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. Gastroenterology 1993; 104: 1736-44.
18. Ohiwa T, Katagiri K, Hoshino M et al. Tauroursodeoxycholate and tauro-beta-muricholate exert cytoprotection by reducing intrahepatocyte taurochenodeoxycholate content. Hepatology 1993; 17: 470-6.
19. Galle PR, Theilmann L, Raedsch R et al. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990; 12: 486-91.
20. Tanaka H, Makino I. Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem Biophys Res Commun 1992; 188: 942-8.
21. Tanaka H, Makino Y, Miura T et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 1996; 156: 1601-8.
22. Mitsuyoshi H, Nakashima T, Inaba K et al. Ursodeoxycholic acid enhances glucocorticoid-induced tyrosine aminotransferase-gene expression in cultured rat hepatocytes. Biochem Biophys Res Commun 1997; 240: 732-6.
23. Yoshikawa M, Tsujii T, Matsumura K et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16: 358-64.
24. Lacaille F, Paradis K. The immunosuppressive effect of ursodeoxycholic acid: A comparative in vitro study on human peripheral blood mononuclear cells. Hepatology 1993; 18: 165-72.
25. Takano S, Ito Y, Yokosuka O et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20: 558-64.
26. Heuman DM, Pandak WM, Hylemon PB et al. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: In vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991; 14: 920-6.
27. Higashidate S, Yamauchi Y, Senda M. Proceedings of the 24th Annual Meeting of Japan Society of Clinical Chemistry. Tokyo: Japan Society of Clinical Chemistry, 1984.
28. Sakakura H, Suzuki M, Kimura N et al. Simultaneous determination of bile acids in rat bile and serum by high-performance liquid chromatography. J Chromatogr 1993; 621: 123-31.
29. Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep 2002; 4: 37-44.
30. Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res 1989; 30: 719-30.
31. Jorgensen RA, Dickson ER, Hofmann AF et al. Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995; 36: 935-8.
32. Crosignani A, Podda M, Battezzati PM et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991; 14: 1000-7.
33. Combes B, Carithers RL Jr, Maddrey WC et al. Biliary bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1999; 29: 1649-54.
34. Mazzella G, Parini P, Bazzoli F et al. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci 1993; 38: 896-902.
35. Batta AK, Salen G, Mirchandani R et al. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol 1993; 88: 691-700.
36. van de Meeberg PC, Wolfhagen FH, Van Berge-Henegouwen GP et al. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. J Hepatol 1996; 25: 887-94.
37. Lindor KD, Lacerda MA, Jorgensen RA et al. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. Am J Gastroenterol 1998; 93: 1498-504.
38. Hofmann AF. Pharmacology of chenodeoxycholic and ursodeoxycholic acids in man. In: Glew RH, ed. Bile Acids nad Cholesterol in Health and Disease. Lancaster: MTP Press, 1983; 301-36.
39. Rossi SS, Converse JL, Hofmann AF. High pressure liquid chromatographic analysis of conjugated bile acids in human bile: Simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids. J Lipid Res 1987; 28: 589-95.
40. Makino I, Nakagawa S. Changes in biliary lipid and biliary bile acid composition in patients after administration of ursodeoxycholic acid. J Lipid Res 1978; 19: 723-8.
41. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part I. Dig Dis Sci 1982; 27: 737-61.
42. Marigold JH, Bull HJ, Gilmore IT et al. Direct measurement of hepatic extraction of chenodeoxycholic acid and ursodeoxycholic acid in man. Clin Sci (Lond) 1982; 63: 197-203.
43. Ishii K, Sora T, Nagai H et al. Background of effective and ineffective patients with chronic hepatitis C treated with urusodeoxycholic acid who are non-responders to interferon therapy. Kanzo 1997; 38: 146-51.
44. Reihner E, Bjorkhem I, Angelin B et al. Bile acid synthesis in humans: regulation of hepatic microsomal cholesterol 7 alpha-hydroxylase activity. Gastroenterology 1989; 97: 1498-505.
45. Heuman DM, Hylemon PB, Vlahcevic ZR. Regulation of bile acid synthesis. III. Correlation between biliary bile salt hydrophobicity index and the activities of enzymes regulating cholesterol and bile acid synthesis in the rat. J Lipid Res 1989; 30: 1161-71.
46. Hagenbuch B, Stieger B, Foguet M et al. Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci USA 1991; 88: 10629-33.
47. Hagenbuch B, Meier PJ. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest 1994; 93: 1326-31.
48. Kullak-Ublick GA, Hagenbuch B, Stieger B et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 1995; 109: 1274-82.
49. Childs S, Yeh RL, Georges E et al. Identification of a sister gene to P-glycoprotein. Cancer Res 1995; 55: 2029-34.
50. Gerloff T, Stieger B, Hagenbuch B et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998; 273: 10046-50.
51. Ishikawa T, Muller M, Klunemann C et al. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J Biol Chem 1990; 265: 19279-86.
52. Kartenbeck J, Leuschner U, Mayer R et al. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996; 23: 1061-6.
53. Fickert P, Zollner G, Fuchsbichler A et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 2001; 121: 170-83.
54. Kurz AK, Graf D, Schmitt M et al. Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 2001; 121: 407-19.
55. Beuers U, Bilzer M, Chittattu A et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 2001; 33: 1206-16.
56. Dombrowski F, Stieger B, Beuers U. Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab Invest 2006; 86: 166-74.
57. Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 318-28.
58. Boyer JL, Trauner M, Mennone A et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1124-30.
59. Marschall HU, Wagner M, Zollner G et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129: 476-85.